The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934, of trading in the securities of CNS Pharmaceuticals Inc. (CNSP) (CIK No. 0001729427), of Houston, Texas at 9:30 a.m. EDT on May 4, 2020, and terminating at 11:59 p.m. EDT on May 15, 2020.

The Commission temporarily suspended trading in the securities of CNSP because of questions regarding the accuracy and adequacy of information in the marketplace about the Company and its securities. Those questions relate to, among other things, statements made by CNSP and others in press releases to investors issued between March 23, 2020 and April 13, 2020 concerning the Company’s business, including the status of development of a drug candidate labeled WP1122, the status of testing WP1122’s impact on COVID-19, and the ability to expedite regulatory approval of any such treatment.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not it has complied with the rule, it should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, it should refrain from entering quotations relating to CNSP’s securities until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation that is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information that may relate to this matter, they should immediately contact Assistant Director Celia Moore at 617-470-4047. The Commission appreciates the assistance of the Financial Industry Regulatory Authority and the Investment Industry Regulatory Organization of Canada.